<DOC>
	<DOC>NCT00637949</DOC>
	<brief_summary>This safety study evaluated the incidence of gastrointestinal adverse events and edema in patients with osteoarthritis treated with lumiracoxib and rofecoxib as comparator</brief_summary>
	<brief_title>Safety of Lumiracoxib in Patients With Osteoarthritis</brief_title>
	<detailed_description />
	<mesh_term>Osteoarthritis</mesh_term>
	<mesh_term>Rofecoxib</mesh_term>
	<mesh_term>Lumiracoxib</mesh_term>
	<mesh_term>Diclofenac</mesh_term>
	<criteria>Age &gt;=50 years old Primary osteoarthritis in hip, hand, knee or spine for at least 3 month Pain in the target joint of moderate intensity Written informed consent Secondary osteoarthritis Active upper gastro intestinal tract ulceration Inflammatory joint disease Gout Clinically significant hepatic or renal disease Other in and exclusion criteria may apply</criteria>
	<gender>All</gender>
	<minimum_age>50 Years</minimum_age>
	<maximum_age>90 Years</maximum_age>
	<verification_date>March 2008</verification_date>
	<keyword>Osteoarthritis</keyword>
	<keyword>lumiracoxib</keyword>
	<keyword>rofecoxib</keyword>
	<keyword>Cox-2</keyword>
	<keyword>Osteoarthritis (primary osteoarthritis hip, hand, knee or spine (cervical or lumbar)</keyword>
</DOC>